Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

Summary

Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate of Roluperidone and antipsychotic medications.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Negative Symptoms of Schizophrenia

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 55 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Minerva Neurosciences

Last updated on ClinicalTrials.gov

July 28, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites